Biotech News

T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens

T2 Biosystems (TTOO)T2 Biosystems2026-06-25 13:46 ESTFDA / regulatory

LEXINGTON, Mass. , Oct. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has entered into a multi-year exclusive U.S.

Open original release

Related news

TTOOT2 Biosystems2026-06-25 13:46 EST

T2 Biosystems, Inc. and Prxcision, Inc. Announce Co-Marketing Collaboration for Rapid Direct-From-Blood Diagnostics and AI-Powered Decision Support Platform

TTOOT2 Biosystems2026-06-25 13:46 EST

T2 Biosystems to Host Business Update Call on October 10, 2024

TTOOT2 Biosystems2026-06-25 13:46 EST

T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024

TTOOT2 Biosystems2026-06-25 13:46 EST

T2 Biosystems Announces Third Quarter 2024 Financial Results

TTOOT2 Biosystems2026-06-25 13:46 EST

T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens

TTOOT2 Biosystems2026-06-25 13:46 EST

T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.

TTOOT2 Biosystems2026-06-25 13:46 EST

T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally

TTOOT2 Biosystems2026-06-25 13:46 EST

T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor

TTOOT2 Biosystems2026-06-25 13:46 EST

T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

NRSNNeuroSense Therapeutics2026-06-25 13:46 EST

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

View all latest news

T2 Biosystems

T2 Biosystems is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

TTOOT2 Biosystems2026-06-26 12:08 EST

T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens

TTOOT2 Biosystems2026-06-26 12:08 EST

T2 Biosystems, Inc. and Prxcision, Inc. Announce Co-Marketing Collaboration for Rapid Direct-From-Blood Diagnostics and AI-Powered Decision Support Platform

TTOOT2 Biosystems2026-06-26 12:08 EST

T2 Biosystems to Host Business Update Call on October 10, 2024

TTOOT2 Biosystems2026-06-26 12:08 EST

T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024

TTOOT2 Biosystems2026-06-26 12:08 EST

T2 Biosystems Announces Third Quarter 2024 Financial Results

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States